

IN THE CLAIMS

This listing of claims replaces the listing of claims in the application.

New Listing of the Claims

1. (Currently Amended) A protein ~~Protein~~ of *N. meningitidis* named NMB0928 characterized by being an antigen able to generate in the recipient organism a protective response against infections caused by bacteria from the *Neisseria* genus and by having the amino acid sequence identified in the sequence list as Seq. ID. No. 4.
2. (Currently Amended) A protein ~~Protein~~ named NMB0928, according to Claim 1, characterized by being codified by gene NMB0928 identified in the sequence list as Seq. ID. No. 3.
3. (Currently Amended) A gene ~~Gene~~ NMB0928 ~~according to Claim 2~~, characterized by having the base sequence identified in the sequence list as Seq. ID. No. 3 and codifying for the protein in Claim 1.
4. (Currently Amended) A protein ~~Protein~~ or peptide obtained by recombinant technology or chemical synthesis, characterized by having the sequence of protein NMB0928 and being able to generate in the recipient organism a protective response against infections caused by bacteria from the *Neisseria* genus according to Claim 1.
5. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ formulation ~~characterized by containing comprising~~ the protein or the peptide of Claim 1 ~~Claims 1, 2 and 4 or the protein of Claim 1 produced by the natural way, according to Claims 1, 2 and 4.~~

6. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ formulation of Claim 5 characterized by being a vaccine able to generate in the recipient organism a protective response against infections caused by bacteria from the *Neisseria* genus.
7. (Currently Amended) Pharmaceutical formulation according to Claim 5 ~~Claims 5 and 6~~ characterized by being a vaccine able to generate in the recipient organism a protective response against infections caused by *Neisseria meningitidis*.
8. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ formulation according to Claim 5 ~~Claims 5 and 6~~ characterized by being a vaccine able to generate in the recipient organism a protective response against infections caused by *Neisseria gonorrhoeae*.
9. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ formulation according to Claim 5 ~~Claims 5, 6, 7 and 8~~, characterized by being a prophylactic or therapeutic formulation.
10. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ formulation according to Claim 5 ~~Claims 5, 6, 7 and 8~~, characterized by being a combined formulation containing one or several antigens of different antigenic nature, obtained by recombinant way, synthetic way or produce by natural way.
11. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ formulation according to Claim 5 ~~Claims 5, 6, 7 and 8~~, characterized as containing polysaccharide antigens.
12. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ formulation according to Claim 5 ~~Claims 5, 6, 7, 8, and 9~~, characterized because one of the components of the formulation is a capsular polysaccharide of *N. meningitidis*.

13. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ formulation according to Claim 9, characterized as containing one polysaccharide-protein conjugate, which polysaccharide moiety corresponds to a bacterial polysaccharide.
14. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ formulation according to Claim 5 ~~Claims 5, 6, 7 and 8~~, characterized as containing one or several inactivated microorganisms
15. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ formulation according to Claim 5 ~~Claims 5, 6, 7 and 8~~, characterized as containing peptide antigens.
16. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ formulation according to Claim 5 ~~Claims 5 and 6~~, characterized as containing hormones.
17. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ formulation according to Claim 5 ~~Claims 5 and 6~~, characterized as containing growth factors.
18. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ formulation according to Claim 5 ~~Claims 5 to 17~~ characterized by being a formulation to be administered by parenteral route.
19. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ formulation according to Claim 5 ~~Claims 5 to 17~~ characterized by being a formulation to be administered by mucosal route.
20. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ formulation according to Claim 5 ~~Claims 5 to 17~~ characterized by being a formulation to be administered by oral route.

21. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ formulation according to Claim 5 ~~Claims 5 to 20~~ characterized by being an immunostimulant or immunopotentiator formulation.

22. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ formulation according to Claim 5 ~~Claims 5 to 21~~ characterized as containing peptides or fragments of the NMB0928 antigen.

23. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ formulation according to Claim 5 ~~Claims 5 to 21~~ characterized as containing mimotopes of the NMB0928 antigen.

24. (Currently Amended) A genetically ~~Genetically~~ modified organism characterized as containing the gene of Claim 3, or part of it, alone or included in another gene sequence.

25. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ formulation according to Claim 24 characterized as containing the genetically modified organism alive, attenuated or a preparation of it.

26. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ formulation characterized as containing the protein expressed by the organism in Claim 24, and being able to generate in the recipient organism a protective response against infections caused by bacteria from the *Neisseria* genus.

27. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ formulation characterized as containing the protein or ~~o~~ the peptide in Claim 1 ~~Claims 1, 2 and 4~~, as carrier of antigens of diverse nature.

28. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ component characterized as containing the protein NMB0928 of Claim 1 ~~Claims 1 and 2~~, or its fragments and being able to allow the detection, alone or in the presence of other components, of the meningococcal disease in humans.

29. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ component characterized as containing the gene of Claim 3, or its fragments and being able to allow the detection, alone or in the presence of other components, of the meningococcal disease in.

30. (Currently Amended) Use of the NMB0928 protein or its fragments, according to Claim 1 ~~Claims 1 and 2~~, in biosensors or other pharmaceutical or biotechnological applications.

31. (Original) Use of the gene NMB0928, according to Claim 3, or its fragments, in biosensors or other pharmaceutical or biotechnological applications.